Entero Therapeutics, Inc. (GRDX) — Defensive Interval Ratio
Entero Therapeutics, Inc. (GRDX) has a Defensive Interval Ratio of 0 days as of September 2025. Defensive assets of $37.49K (cash $-, short-term investments $-, receivables $37.49K) cover 0 days of daily cash needs of $91.83K/day. Check Entero Therapeutics, Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Entero Therapeutics, Inc. Defensive Interval Ratio (2014–2022)
This chart shows how Entero Therapeutics, Inc.'s Defensive Interval Ratio has evolved across 8 annual periods from 2014 to 2022. As of September 2025, the ratio stands at 0 days, meaning defensive assets of $37.49K can fund 0 days of operations without new revenue. Also explore GRDX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for Entero Therapeutics, Inc. (2014–2022)
The table below presents the year-by-year Defensive Interval Ratio for Entero Therapeutics, Inc. from 2014 to 2022, covering 8 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Entero Therapeutics, Inc. stock valuation.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2022 | 14 days | $93.01K | $6.80K/day | $- | $- | ▲ +1 days |
| 2020 | 13 days | $551.49K | $42.59K/day | $- | $- | ▼ -212 days |
| 2019 | 225 days | $2.64 Million | $11.74K/day | $- | $- | ▼ -162 days |
| 2018 | 387 days | $3.17 Million | $8.21K/day | $- | $- | ▲ +343 days |
| 2017 | 44 days | $298.47K | $6.79K/day | $- | $- | ▼ -106 days |
| 2016 | 150 days | $961.04K | $6.41K/day | $- | $- | ▲ +103 days |
| 2015 | 47 days | $1.13 Million | $24.15K/day | $- | $56.85K | ▼ -36 days |
| 2014 | 83 days | $553.82K | $6.66K/day | $- | $125.07K | — |